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Abstract
Introduction:  Molecular  studies  about  carcinomas  of  the  oral  cavity  and  oropharynx  demon-
strate the  presence  of  human  papilomavirus  genome  in  these  tumors,  reinforcing  the
participation  of  human  papilomavirus  in  oral  carcinogenesis.
Objectives:  This  study  aimed  to  determine  the  prevalence  of  human  papilomavirus  and  geno-
type distribution  of  HPV16  and  HPV18  in  oral  cavity  and  oropharynx  carcinomas,  as  well  as  their
association  with  clinical  characteristics  of  the  tumors.
Methods:  This  is  a  retrospective  study,  with  clinical  data  collected  from  82  patients.  Human
papilomavirus  detection  was  conducted  on  specimens  of  oral  cavity  and  oropharynx  carcinomas
included  in  parafﬁn  blocks.  Patients  were  assisted  in  a  cancer  reference  center,  in  the  central
region of  Brazil,  between  2005  and  2007.  Polymerase  chain  reaction  was  used  for  the  detection
and genotyping  of  human  papilomavirus.
Results:  Among  the  patients  evaluated,  78%  were  male.  The  average  age  of  the  group  was  about
58 years.  Risk  factors,  such  as  smoking  (78%)  and  alcohol  consumption  (70.8%)  were  recorded
for the  group.  HPV  DNA  was  detected  in  21  cases  (25.6%;  95%  conﬁdence  interval  16.9--36.6)
of which  33.3%  were  HPV16  and  14.3%  were  HPV18.  The  presence  of  lymph  node  metastases
and registered  deaths  were  less  frequent  in  human  papilomavirus  positive  tumors,  suggesting
a better  prognosis  for  these  cases;  however,  the  differences  between  the  groups  were  not
statistically  signiﬁcant.
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Conclusion:  The  results  obtained  in  the  present  study,  with  respect  to  the  presence  of  the  high-
risk HPV16  and  HPV18  genotypes,  highlight  the  importance  of  human  papilomavirus  vaccination
in the  control  of  oral  cavity  and  oropharynx  carcinomas.
© 2016  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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Papilomavírus  humano  (HPV)  em  carcinomas  de  cavidade  oral  e  orofaringe  na  região
central  do  Brasil
Resumo
Introduc¸ão:  Estudos  moleculares  sobre  carcinomas  da  cavidade  oral  e  orofaringe  demonstram
a presenc¸a  do  genoma  do  papilomavírus  humano  (HPV)  nesses  tumores,  o  que  enfatiza  a
participac¸ão do  HPV  na  carcinogênese  oral.
Objetivos:  Esse  Este  estudo  teve  por  objetivo  determinar  a  prevalência  de  HPV  e  a  distribuic¸ão
genotípica  de  HPV16  e  HPV18  nos  carcinomas  de  cavidade  oral  e  orofaringe,  bem  como  sua
associac¸ão com  as  características  clínicas  dos  tumores.
Método:  Este  é  um  estudo  retrospectivo,  com  dados  clínicos  coletados  de  82  pacientes.  A
detecc¸ão de  HPV  foi  realizada  em  amostras  de  carcinomas  de  cavidade  oral  e  orofaringe  incluí-
dos em  blocos  de  paraﬁna.  Os  pacientes  foram  atendidos  em  um  centro  de  referência  para
tratamento  do  câncer,  na  região  central  do  Brasil,  entre  2005  e  2007.  Foi  utilizada  a  reac¸ão  em
cadeia de  polimerase  (PCR)  para  a  detecc¸ão  e  genotipagem  do  HPV.
Resultados:  Entre  os  pacientes  avaliados,  78%  eram  homens.  A  média  de  idade  do  grupo  era
de 58  anos.  Fatores  de  risco  como  o  tabagismo  (78%)  e  consumo  de  álcool  (70.,8%)  foram
registrados  para  o  grupo.  HPV  DNA  foi  detectado  em  21  casos  (25,6%;  IC  de  95%,  16,9---36,6),
dos quais  33,3%  eram  HPV16  e  14,3%  eram  HPV18.  A  presenc¸a  de  metástases  em  linfonodos  e  os
óbitos registrados  foram  menos  frequentes  em  tumores  positivos  para  HPV,  sugerindo  melhor
prognóstico  para  esses  casos;  contudo,  as  diferenc¸as  entre  os  grupos  não  foram  estatisticamente
signiﬁcantes.
Conclusão:  Os  resultados  obtidos  no  presente  estudo,  com  respeito  à  presenc¸a  de  genótipos  de
alto risco  de  HPV16  e  HPV18,  destacam  a  importância  da  vacinac¸ão  para  HPV  no  controle  dos
carcinomas  de  cavidade  oral  e  orofaringe.
© 2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY
(http://creativecommons.org/licenses/by/4.0/).
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ead  and  neck  cancers  (HNC),  including  oral  cavity  and
ropharynx  carcinomas,  are  the  sixth  most  common  can-
er  types  in  the  world,  with  an  annual  estimate  of  633,000
ew  cases  and  355,000  deaths.1 In  Brazil,  15,290  HNCs  were
xpected  in  2014,  with  11,280  cases  in  men  and  4010  in
omen.2
Oral  and  oropharynx  carcinomas  account  for  more  than
0%  of  the  total  HNC  cases,3 and  squamous  cell  carcinoma
SCC)  is  the  most  common  histological  type,  comprising  more
han  90%  of  the  cases.  The  prognosis  of  these  tumors  is
ostly  pessimistic,  with  a  low  ﬁve-year  survival  of  approxi-
ately  58%.4,5
Age,  gender,  and  tumor-node-metastasis  (TNM)  tumor
taging,  which  includes  the  extension  of  the  tumor,  the  pres-
nce  of  lymph  node  metastases,  and  distant  metastasis,  are
he  main  prognostic  factors  for  oral  cavity  and  orophar-
nx  carcinomas.6 In  addition,  histological  grade  and  the
y
e
cxpression  of  molecular  markers  (p16,  pRb,  and  Ki-67)  allow
 better  understanding  of  tumor  behavior  and  evolution.6--8
The  treatment  of  SCC  of  the  oral  cavity  and  orophar-
nx  is  usually  accomplished  by  surgery  or  radiotherapy,
lone  or  associated,  and  may  also  include  the  use  of
hemotherapy  as  an  alternative  to  improve  the  chances
f  cure.9 Studies  suggest  that  for  Human  papillomavirus
HPV)-positive  oral  cavity  and  oropharynx  SCC,  treatment
ith  surgery  and  adjuvant  radiotherapy  is  as  good  as
he  deﬁnitive  radiotherapy  treatment,  with  or  without
hemotherapy.9,10
Smoking  and  alcohol  consumption  are  considered  the
ain  risk  factors  for  oral  cavity  and  oropharynx  cancer.9--11
owever,  with  the  intensiﬁcation  of  campaigns  against
moking  and  alcohol,  the  role  of  HPV  in  oral  cavity  and
ropharynx  carcinomas  has  gained  prominence  in  recent
11,12ears. A  growing  number  of  studies  support  the  hypoth-
sis  of  HPV  association  with  oral  cavity  and  oropharynx
arcinomas.10--14
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Human  papillomavirus  in  oral  cavity  and  oropharynx  carcino
HPV  is  a  sexually-transmitted  infection;  therefore,  fac-
tors  such  as  early  initiation  of  sexual  activity,  high  number
of  sex  partners,  and  the  practice  of  unprotected  oral  sex  are
included  as  risk  factors  for  HPV  infection  in  the  oral  cavity
and  oropharynx  mucosa.15 Growing  incidence  of  oral  cavity
and  oropharynx  carcinomas  associated  with  HPV  in  young
people  has  been  demonstrated.14--16
The  prevalence  of  HPV  in  oral  cavity  and  oropharynx  SCC
is  the  focus  of  several  studies  worldwide;  HPV16  is  con-
sidered  the  most  prevalent  and  relevant  genotype  in  the
epidemiology  of  these  carcinomas.13,17--20
This  study  aimed  to  investigate  the  prevalence  and  geno-
typic  distribution  of  HPV16  and  HPV18  in  oral  cavity  and
oropharynx  carcinomas,  as  well  as  their  possible  association
with  the  clinical  characteristics  of  the  tumors.
Methods
Type  of  study  and  series
The  study  was  approved  by  the  Research  Ethics  Committee,
under  No.  13580613.5.0000.0031/2014.  It  was  a  retrospec-
tive  cross-sectional  study  that  used  data  collected  from
medical  ﬁles  and  analysis  of  parafﬁn  blocks  containing
specimens  of  oral  cavity  and  oropharynx  carcinomas.  The
selection  was  ﬁrst  accomplished  by  analyzing  the  records
of  the  Pathology  Department  at  the  Hospital,  and  only
patients  with  histological  diagnosis  of  SCC  of  oral  cavity  and
oropharynx  were  included.  Initially  312  cases  of  SCC  diag-
nosed  in  the  period  from  2005  to  2007  were  selected.  After
eliminating  duplicates,  174  cases  with  available  clinical
records  were  selected.  Patients  who  received  chemother-
apy/radiotherapy  before  surgery  were  excluded,  resulting  in
108  cases.  Parafﬁn  blocks  from  108  cases  were  histologically
examined,  and  specimens  with  exiguous  amount  of  tumors
were  excluded,  resulting  in  82  cases  that  were  selected  for
DNA  extraction  and  HPV  DNA  detection.
DNA  extraction
Genomic  DNA  was  puriﬁed  from  tumor  samples  ﬁxed  in  for-
malin  and  included  in  parafﬁn.  The  samples  were  dewaxed
in  xylene  and  washed  in  ethanol  according  to  standardized
protocol.  DNA  was  isolated  by  using  the  commercial  Wizard
Kit  (Promega).  The  presence  and  the  integrity  of  the  DNA
were  veriﬁed  by  the  ampliﬁcation  of  a  99  base  pair  (BP)
fragment  from  glyceraldehyde-3-phosphate  dehydrogenase
(GAPDH),  by  using  polymerase  chain  reaction  (PCR).
HPV  DNA  detection
HPV  DNA  was  detected  by  PCR.  The  set  of  primers  used
was  SPF  1/2  (short  PCR  fragment).  The  SPF  1/2  ampliﬁes
a  fragment  of  65  pb  of  the  L1  region  of  HPV  genome.  This
set  of  primers  allow  the  detection  of  39  high  and  low  onco-
genic  risk  HPV:  6,  11,  13,  18,  26,  30,  31,  33,  34,  35,  39,
40,  42,  43,  44,  45,  51,  52,  53,  54,  55,  56,  58,  59,  61,  62,
64,  66,  67,  68,  69,  70,  72,  MM4,  MM7,  73,  74,  and  MM8.
The  genotypes  detected  by  SPF  1/2  are  those  that  infect
the  mucous  membrane.13 PCR  with  SPF  1/2  primers  was
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arried  out  in  a  ﬁnal  reaction  volume  of  25  L,  adding  2  L  of
uriﬁed  DNA,  2.5  mM/L  MgCl2,  2  mM/L  of  each  deoxyribonu-
leotide  (dNTPs),  2.5  M/L  of  each  oligonucleotide  primer,
.25  U  Taq  polymerase  (Invitrogen,  Brazil)  and  ultra  pure
ater  in  sufﬁcient  quantity  for  the  ﬁnal  volume.  Cycling  con-
itions  included:  preheating  for  1  min  at  94 ◦C,  followed  by
0  cycles  of:  94 ◦C  for  1  min,  1  min  at  45 ◦C,  and  1  min  at
2 ◦C,  with  a  ﬁnal  extension  of  5  min  at  72 ◦C.  Positive  and
egative  controls  were  used  in  each  reaction.
enotyping  of  HPV16  and  18
PV16  and  HPV18  genotyping  was  performed  by  PCR  for  all
PV-positive  tumors.  Two  sets  of  primers  that  amplify  part
f  E7  region  of  each  HPV  genome  were  employed.21 For  the
PV16  genome,  the  amplicon  presents  108  pb,  and  for  HPV18
enome  ampliﬁcation,  the  amplicon  presents  104  pb.  PCR
ith  HPV16  primers  was  performed  in  a  ﬁnal  reaction  vol-
me  of  25  L,  with  2  L  of  puriﬁed  DNA,  2.5  mM/L  MgCl2,
 mM/L  of  each  dNTPs,  2.5  M/L  of  each  oligonucleotide
rimer,  0.25  U  Taq  polymerase  (Invitrogen,  Brazil),  and  ultra
ure  water  in  sufﬁcient  quantity  for  the  ﬁnal  volume.  Cycling
onditions  included:  preheating  for  1  min  at  94 ◦C,  followed
y  40  cycles  of:  94 ◦C  for  1  min,  1  min  at  45 ◦C,  and  1  min
t  72 ◦C,  with  a  ﬁnal  extension  of  5  min  at  72 ◦C.  PCR  with
PV18  primers  was  performed  in  a  ﬁnal  reaction  volume  of
5  L,  with  5  L  of  puriﬁed  DNA,  2.5  mM/L  MgCl2, 2  mM/L  of
ach  dNTPs,  2.5  M/L  of  each  oligonucleotide  primer,  1.25  U
aq  polymerase,  (Invitrogen,  Brazil)  and  ultra  pure  water  in
ufﬁcient  quantity  for  the  ﬁnal  volume.  Cycling  conditions
ncluded:  preheat  for  3  min  at  94 ◦C,  followed  by  35  cycles
f:  1  min  at  94 ◦C,  1  min  at  53 ◦C,  and  1  min  at  72 ◦C,  with  a
nal  extension  of  3  min  at  72 ◦C.
tatistical  analysis
ll  the  patients’  data  were  transcribed  to  Microsoft  Excel®
preadsheets.  Clinical  and  histological  data  of  the  group,
s  well  as  the  presence  of  HPV  genome,  HPV16,  and  HPV18
enotypes  were  analyzed  by  using  Fisher’s  exact  test  and  the
hi-squared  test.  Values  of  p  ≤  0.05  were  considered  statis-
ically  signiﬁcant.  Positive  and  negative  controls  were  used
n  each  reaction.
esults
linical  and  histological  characteristics:  a  group  of  82  cases
f  SCC  of  oral  cavity  and  oropharynx  were  selected  and
valuated  with  respect  to  clinical  and  histological  charac-
eristics  (Table  1).  Among  the  patients,  78%  were  male.
ost  of  the  patients  (54.9%)  were  in  the  age  group  under  59
ears  and  62.2%  were  married.  Risk  factors,  such  as  smok-
ng  (78%)  and  alcohol  consumption  (70.8%)  were  recorded
or  the  majority  of  the  group.  Data  associated  with  sexual
ehavior  and  orientation,  such  as  the  number  of  sexual  part-
ers,  age  at  sexual  activity  onset,  and  practice  of  oral  sex
ere  not  reported  in  the  medical  ﬁles.
HPV  detection  and  genotyping:  HPV  DNA  was  detected  in
1  cases  (25.6%;  95%  conﬁdence  interval  (CI)  16.9--36.6),  of
hich  33.3%  were  HPV16  and  14.3%  were  HPV18.  Table  2
escribes  the  clinical  characteristics  of  HPV-positive  and
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Table  1  Analysis  of  the  clinical  and  histological  charac-
teristics  of  the  patients  with  oral  cavity  and  oropharynx
carcinomas.
Variable  All  cases  (n  =  82)
n  %
Gender
Female  18  22.0
Male 64  78.0
Age at  diagnosis
Average 58  --
≤59 45  54.9
≥60 37  45.1
Marital  status
Single  15  18.2
Married  51  62.2
Other 16  19.6
Smoking
Yes 64  78.0
No 18  22.0
Alcohol  consumption
Yes 58  70.8
No 24  22.0
Tumor  location
Oral  cavity  39  47.6
Oropharynx  43  52.4
Staging
I/II 14  17.1
III/IV 68  82.9
Tumor  size
T1  and  T2  35  42.7
T3 and  T4  47  57.2
Lymph  node  metastasis
Yes  42  51.2
No 40  48.8
Distant  metastases
Yes  01  1.2
No 81  98.8
Histological  grade
Low  13  15.8
Moderate/high  69  84.2
Registered  death
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qYes  28  34.1
No 54  65.9
egative  cases.  Among  the  21  HPV-positive  samples,  47.4%
ere  located  in  the  oral  cavity  and  52.6%  in  oropharynx.
onsidering  the  clinical  staging  for  HPV-positive  tumors,
.8%  were  in  stages  I/II,  while  95.2%  were  in  stages  III/IV.
ymph  node  metastases  were  detected  in  42.9%  of  HPV-
ositive  cases  and  in  57.4%  of  HPV-negative  cases  (p  =  0.08).
istant  metastases  were  not  detected  in  HPV-positive  cases,
hile  one  distant  metastasis  was  described  in  the  HPV-
egative  cases  (p  =  0.46).  With  respect  to  histological  grade,
5.7%  of  HPV-positive  cases  showed  moderate  to  high  grade
t
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f  differentiation.  A greater  number  of  deaths  were  reg-
stered  in  the  HPV-negative  group  (39.3%)  compared  to
he  HPV-positive  group  (19.1%),  though  this  difference  was
ot  statistically  signiﬁcant  (p  =  0.11).  With  respect  to  HPV
enotyping,  seven  samples  (33.3%)  were  HPV16  positive,
hile  three  samples  (14.3%)  were  HPV18  positive.  Signiﬁ-
ant  differences  between  HPV16  and  HPV18  tumors  were
ot  detected  in  this  study.
iscussion
n  this  study  analyzing  82  cases  of  SCC  of  oral  cavity  and
ropharynx  diagnosed  in  a  cancer  reference  center  in  the
entral  region  of  Brazil.  HPV  DNA  was  detected  in  21  cases
25.6%),  of  which  33.3%  were  HPV16  and  14.3%  were  HPV18.
hese  results  support  the  hypothesis  that  a  subgroup  of  oral
avity  and  oropharynx  carcinomas  is  HPV  related.12--18 Sig-
iﬁcant  changes  in  the  epidemiology  of  mucosal  SCCs  of  the
ead  and  neck,  with  an  increasing  number  of  cases  related
o  HPV,  have  been  demonstrated  in  the  last  decade.1--22 In
ddition  to  tobacco  and  alcohol  consumption,  HPV  appears
s  an  important  risk  factor  for  oral  cavity  and  oropharynx
CC  development.  The  prevalence  of  HPV  DNA  in  oropharyn-
eal  cancer  (OC)  varies  in  different  studies,  and  up  to  84%
f  cases  have  been  associated  to  HPV  infection.19
The  association  between  HPV  infection  with  oral  cavity
nd  oropharynx  SCC  emphasizes  the  importance  of  introduc-
ng  speciﬁc  molecular  tests  into  oral  cancer  prevention
ractices,  in  order  to  evaluate  the  presence  of  the  virus  and
he  possibility  of  expanding  anti-HPV  vaccine  in  the  male
opulation.23,24
In  the  present  study,  54.9%  of  the  patients  were  younger
han  59  years.  Several  studies  describe  the  age  range  of  the
atients  with  carcinoma  of  oral  cavity  and  oropharynx  as
imilar  to  the  value  described  in  the  present  study.25,26 In  a
tudy  conducted  in  Italy,  the  median  age  was  65.6  years.18
he  accumulation  of  exposure  to  various  risk  factors,  such
s  lifelong  smoking  and  alcoholism,  contributes  to  the
igher  prevalence  of  these  tumors  in  more  advanced  ages.6
tudies  demonstrated  that  HPV-associated  HNC,  including
ropharyngeal  and  oral  cavity  SCCs,  have  recently  risen  dra-
atically  in  men  under  50  years  old.27 In  a period  of  20
ears,  the  relative  prevalence  of  HPV-positive  oropharyn-
eal  squamous  cancer  cell  (OSCC)  went  from  less  than  20%
o  more  than  70%  in  the  United  States  and  some  European
ountries.28--30 In  the  HPV-positive  patients  evaluated  in  the
resent  series,  66.7%  of  the  cases  were  under  the  average
ge  (59  years).  Most  cases  of  carcinoma  of  the  oral  cav-
ty  and  oropharynx  were  observed  in  males  (78.0).  Various
uthors  have  previously  reported  this  information;  however,
n  different  countries  of  Europe,  an  increasing  tendency  in
he  incidence  of  oropharynx  carcinomas  has  been  noticed  in
emales.9--29
Smoking  and  alcohol  consumption  are  described  as  the
ain  risk  factors  for  carcinomas  of  the  oral  cavity  and
ropharynx.11--31 The  present  study  conﬁrmed  the  high  fre-
uency  of  smokers  (78.0%)  and  alcohol  drinkers  (70.8%)  in
he  group.  Although  not  fully  considered  as  a  prognostic  fac-
or,  carcinomas  of  the  oral  cavity  and  oropharynx  associated
ith  smoking  and  alcoholism  tend  to  be  more  aggressive.1
obacco  and  alcohol  can  induce  SCC  of  the  oral  cavity  and
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Table  2  Analysis  of  the  clinical  and  histological  characteristics  of  the  patients  with  HPV-positive  and  HPV-negative  oral  cavity
and oropharynx  carcinomas.
Variable  HPV  (−)  (n  =  61)  HPV  (+)  (n  =  21)  pa
n  %  n  %
Gender
Female  15  24.6  03  14.3  0.38
Male 46  75.4  18  85.7
Age at  diagnosis
Average 60  -- 53  --  0.31
≤59 31 50.8 14  66.7
≥60 30  49.2  07  33.3
Tumor location
Oral  cavity  29  47.5  10  47.4  1.00
Oropharynx 32  54.5  11  52.6
Staging
I and  II  13  21.3  1  4.8  0.10
III and  IV  48  78.7  20  95.2
Tumor size
T1  and  T2  26  42.6  09  33.3  1.00
T3 and  T4  35  57.4  12  66.7
Lymph node  metastasis
Yes  35  57.4  07  42.9  0.08
No 26  42.6  14  57.1
Remote metastases
Yes  01  1.6  00  0.00  0.46
No 60  98.4  21  100.0
Grade of  differentiation
Low  10  16.4  03  14.3  1.00
Moderate, high 51  83.6  18  85.7
Registered deaths
Yes  24  39.3  04  19.1  0.11
No 37  60.6  17  80.9
Treatment
Surgery only  24  39.5  03  14.3  0.32
Surgery +  radiotherapy  14  22.9  08  38.1
Radiotherapy  +  chemotherapy  09  14.7  03  14.3
Other 14  22.9  07  33.3
HPV type
HPV16  --  --  07  33.3
HPV18 --  --  03  14.3
Other --  --  11  42.4
m
c
s
b
n
p
Ha All p-values were calculated with Fischer’s exact test.
oropharynx  by  aggression  on  extensive  areas,  leading  to  a
phenomenon  known  as  ﬁeld  cancerization,  which  is  charac-
terized  by  molecular  changes  in  the  reserve  cells,  leading  to
the  formation  of  epithelial  ﬁeld  changes.26 This  ﬁeld  under-
goes  expansion  and  extends  over  the  surface  of  the  mucous
membrane,  increasing  the  possibility  of  formation  of  a  new
carcinoma.32,33The  proﬁle  of  patients  with  carcinoma  of  the  oral  cavity
and  oropharynx  associated  with  HPV  tends  to  be  charac-
terized  by  a  group  of  younger  patients,  aged  less  than  60
years,  non-smokers  or  light  smokers,  non-drinkers,  and  with
g
n
d
Iore  promiscuous  sexual  behavior;  however,  these  data  are
ontroversial.34,35 One  important  limitation  of  the  present
tudy  is  the  lack  of  data  related  to  the  patients’  sexual
ehavior.  Since  it  was  a  retrospective  study,  such  data  were
ot  available  in  the  medical  ﬁles.  Although  a  higher  pro-
ortion  of  patients  were  described  under  59  years  in  the
PV-positive  group  (66.7%)  compared  to  the  HPV-negative
roup  (50.8%),  these  differences  were  not  statistically  sig-
iﬁcant.  Similar  results  with  respect  to  age  group  were
escribed  in  two  studies  developed  in  the  United  States.13,14
n  the  present  study,  the  average  age  for  HPV-positive
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atients  was  lower,  53  years,  compared  to  the  HPV-negative
roup,  60  years.  A  study  conducted  in  Colombia  conﬁrmed
 lower  average  age  for  HPV-positive  patients  with  oral
avity  and  oropharynx  carcinomas.12 Signiﬁcant  associations
etween  the  presence  of  HPV  and  the  absence  of  habits  like
moking  and  alcohol  consumption  were  not  noticed  in  the
resent  study,  corroborating  with  various  studies.6--18
The  prognosis  of  oral  cavity  and  oropharynx  carcinomas
s  uncertain  and  difﬁcult  to  predict.4 The  identiﬁcation  of
actors  that  may  help  choosing  the  best  treatment,  predict-
ng  the  evolution  of  the  tumor  as  well  as  patient’s  survival,
s  of  evident  clinical  importance.  HPV-positive  oral  cavity
nd  oropharynx  SCC  seem  to  present  a  better  prognosis
hen  treated  with  surgery  and  adjuvant  radiotherapy  or
adiation  therapy  with  or  without  ﬁnal  chemotherapy.10 Lim-
tations  on  data  collection  in  the  present  study  prevented  a
urvival  analysis  associated  with  the  therapy  used.  A  system-
tic  review  highlights  the  importance  of  evaluating  patients
ith  HPV-related  oropharyngeal  carcinomas,  in  order  to
redict  the  best  therapy,  since  these  virus-associated  car-
inomas  show  distinct  molecular  characteristics  compared
o  HPV-negative  ones.9 However,  currently,  only  a  few  stud-
es  describe  a  direct  association  between  treatment,  the
resence  of  the  HPV  genome,  and  survival.9,10
A  better  prognosis  for  HPV-positive  oral  cavity  and
ropharynx  carcinomas  has  been  described  in  a  few  studies,
ncluding  well-differentiated  tumors,  with  less  risk  of  lymph
ode  metastasis  and  distant  metastasis.9--36 In  the  present
tudy,  these  characteristics  were  observed;  however,  the
ifference  between  the  groups  was  not  signiﬁcant.  Distant
etastases  were  not  described  in  the  HPV-positive  group,
lthough  only  one  case  of  HPV-negative  tumors  presented
ith  distant  metastases.  Concerning  the  presence  of  lymph
ode  metastasis,  a  lower  rate  of  lymph  node  metastasis  was
bserved  in  the  HPV-positive  tumors  (42.9%  vs.  57.4%),  sug-
esting  a  better  prognosis  for  these  tumors;  however,  such
ifferences  were  not  statistically  signiﬁcant.
HPV16  and  HPV18  are  described  as  the  most  preva-
ent  genotypes  in  oral  cavity  and  oropharynx  carcinomas,
nd  their  association  with  these  carcinomas  seems  to  be
elevant.14 In  the  present  study,  of  the  21  HPV-positive  sam-
les,  HPV16  was  described  in  33.3%  and  HPV18  in  14.3%  of
he  tumors.  To  describe  the  prevalence  of  HPV16  and  18  in
ral  cavity  and  oropharynx  carcinomas  is  important  in  order
o  predict  the  impact  of  vaccination  on  these  tumors,  since
oth  genotypes  are  the  main  targets  for  the  bivalent  (16/18)
nd  quadrivalent  vaccines  (11/16/18/6).15--27 In  the  present
tudy,  no  signiﬁcant  differences  were  described  regarding
he  staging  and  death  of  the  patients  when  comparing  HPV16
nd  18  positive  and  negative  cases.
Recent  reports  highlight  that  vaccination  campaigns  are
n  efﬁcient  solution  for  the  control  of  the  HPV-associated
arcinomas.15--37 Regarding  this  connection  and  considering
he  high  prevalence  of  HPV  in  oral  cavity  and  oropharynx
arcinomas  in  males,  it  is  extremely  important  that  this
ampaign  might  also  be  extended  to  the  male  group.
In  the  present  study,  the  presence  of  HPV  was  detected
n  25.6%  of  the  cases,  including  types  16  and  18,  lead-
ng  to  the  conclusion  that  HPV  is  also  associated  with  the
evelopment  of  oral  cavity  and  oropharyngeal  carcinomas.
his  study  presented  an  important  limitation  with  respect
o  clinical  and  behavioral  data  of  the  patients.  In  the
1 PRESS
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edical  ﬁles,  such  data  were  scarce,  including  sexual  behav-
or,  oral  hygiene,  history  of  sexually  transmitted  diseases,
nd  patient  follow-up,  among  others.  These  difﬁculties  are
nherent  to  retrospective  studies,  since  the  researchers  rely
nly  on  the  information  present  in  medical  records  that  can
ften  be  lost,  incomplete,  or  unclear.20--30
The  authors  suggest  a  prospective  study,  with  more  efﬁ-
ient  data  collection  and  patient  follow-up,  allowing  a  more
ccurate  and  complete  survey,  with  a larger  number  of  cases
rom  different  oncology  centers  in  the  country,  in  order  to
mprove  the  knowledge  of  HPV  carcinogenesis  in  oral  cavity
nd  oropharynx  carcinomas.
onclusions
his  study  conﬁrms  the  higher  prevalence  of  HPV  DNA  in
ral  cavity  and  oropharynx  carcinomas,  especially  in  males
78%),  with  an  average  age  of  58  years,  and  a  high  frequency
f  smokers  and  alcohol  drinkers.
The  prevalence  of  HPV  DNA  genome  in  the  samples  ana-
yzed  was  25.6%,  and  among  the  positive  cases,  33.3%  were
PV16  and  14.3%  were  HPV18,  highlighting  the  association  of
igh-risk  HPV  in  oral  cavity  and  oropharynx  carcinogenesis.
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